Synergistyczne działanie flukonazolu i laktonów ftalidowych jako czynnik ograniczający stosowanie leków azolowych w leczeniu kandidoz

• Autorzy: Olejniczak Teresa

Identyfikatory

DOI

10.53584/wiadchem.2023.05.7

Warianty tytułu

EN

Synergistic effect of fluconazole and phtalide lactones as a factor limiting the use of azole drugs against candidiasis

• Języki publikacji: PL

Abstrakty

EN

The resistance of Candida albicans and other pathogenic yeasts to azole antifungal drugs has increased rapidly in recent years and is a significant problem in clinical therapy. The current state of pharmacological knowledge precludes the withdrawal of azole drugs, as no other active substances have yet been developed that could effectively replace them. Therefore, one of the anti-yeast strategies may be therapies that can rely on the synergistic action of natural compounds and azoles, limiting the use of azole drugs against candidiasis. Synergy assays perperformed in vitro were used to assess drug interactions Fractional Inhibitory Concentration Index. The synergistic effect of fluconazole (1) and three synthetic lactones identical to those naturally occurring in celery plants—3-n-butylphthalide (2), 3-n-butylidenephthalide (3), 3-n-butyl-4,5,6,7-tetrahydrophthalide (4)—against Candida albicans ATCC 10231, C. albicans ATCC 2091, and C. guilliermondii KKP 3390 was compared with the performance of the individual compounds separately. MIC90 (the amount of fungistatic substance (in µg/mL) inhibiting yeast growth by 90%) was determined as 5.96–6.25 µg/mL for fluconazole (1) and 92–150 µg/mL for lactones 2–4. With the simultaneous administration of fluconazole (1) and one of the lactones 2–4, it was found that they act synergistically, and to achieve the same effect it is sufficient to use 0.58–6.73 µg/mL fluconazole (1) and 1.26–20.18 µg/mL of lactones 2–4. Based on biological research, the influence of the structure on the fungistatic activity and the synergistic effect were determined.

Słowa kluczowe

PL

efekt synergii; Candida albicans; laktony ftalidowe; flukonazol

EN

synergistic effect; Candida albicans; phthalide lactones; fluconazole

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2023
• Tom: [Z] 77, 5-6
• Strony: 555--567
• Opis fizyczny: Bibliogr. 49 poz., rys., tab., wykr.

Twórcy

autor

Olejniczak Teresa

• Wydział Biotechnologii i Nauk o Żywności, Uniwersytet Przyrodniczy we Wrocławiu, ul. C. K. Norwida 25, 50-375 Wrocław

• https://orcid.org/0000-0001-6156-5820

Bibliografia

• [1] B. Mishra, A.K. Mishra, S. Kumar, S.K. Mandal, Kumar, K.-H. Baek, Y.K. Mohanta, Metabolites 2021, 12, 12.
• [2] D.K. Singh, R. Tóth, A. Gácser, Front. Cell. Infect. Microbiol. 2020, 10, 94.
• [3] M. Staniszewska, Ł. Kuryk, A. Gryciuk, J. Kawalec, M. Rogalska, J. Baran, E.Łukowska-Chojnacka,; Kowalkowska, A. Molecules 2021, 26, 5008.
• [4] R.A. Smego, H. Ahmad, Medicine 2011, 90, 237.
• [5] M.E. Akler,. H.Vellend, D.M. McNeely, S.L. Walmsley, W.L. Gold, Clin. Infect. Dis. 1995, 20, 657.
• [6] D.F. Bavaro, F. Balena, L. Ronga, F. Signorile, F. Romanelli, S. Stolfa, E. Sparapano, C. de Carlo, A. Mosca, L. Monno, i inni. J. Med. Mycol. 2022, 32, 101206.
• [7] J.C.R. Corrêa, H.R.N. Salgado, Crit. Rev. Anal. Chem. 2011, 41, 124.
• [8] N. Fattouh, D. Hdayed, G. Geukgeuzian, S. Tokajian, R.A. Khalaf, Fungal Genet. Biol. 2021, 153, 103575.
• [9] M.A. Jacobson, D.K. Hanks, L.D. Ferrell, Am. J. Med. 1994, 96, 188.
• [10] T. Bühler, M. Medinger, J. Bouitbir, S.Krähenbühl, A. Leuppi-Taegtmeyer, Front. Pharmacol. 2019, 10, 645.
• [11] K.R. Beck, A. Odermatt, Mol. Cell. Endocrinol. 2021, 524, 111168.
• [12] S. Bhattacharya, S. Sae-Tia, B.C. Fries, Antibiotics 2020, 9, 312.
• [13] A. Agrawal, A. Singh, R. Verma, A. Murari, J. Oral Maxillofac. Pathol. 2014, 18, 81.
• [14] K. Spettel, W. Barousch, A. Makristathis, I. Zeller, M. Nehr, B. Selitsch, M. Lackner, P.-M. Rath, J. Steinmann, B. Willinger, PLOS ONE 2019, 14, e0210397.
• [15] M.T. Yassin, A.A. Mostafa, A.A. Al-Askar, R. Bdeer, Eur. J. Med. Res. 2020, 25, 1.
• [16] Becher, R.; Wirsel, S.G.R. Appl. Microbiol. Biotechnol. 2012, 95, 825.
• [17] P.-Y. Chen, Y.-C. Chuang, U.-I. Wu, H.-Y. Sun, J.-T. Wang, W.-H. Sheng, Y.-C. Chen, S.-C. Chang, S.-C. J. Fungi 2021, 7, 612.
• [18] A .Arastehfar, F. Daneshnia, A. Hafez, S. Khodavaisy, M.J. Najafzadeh, A. Charsizadeh, H. Zarrinfar, [23]Med. Mycol. 2020, 58, 766.
• [19] X. Fan, M.Xiao, D. Zhang, , J.J. Huang, H. Wang, X. Hou, L. Zhang, F. Kong, S.C Chen, Z.H. Tong, i inni Clin. Microbiol. Infect. 2019, 25, 885.
• [20] S.A. Flowers, B Colón, S.G. Whaley, M.A. Schuler, P.D. Rogers, Antimicrob. Agents Chemother. 2015, 59, 450.
• [21] K.E. Pristov, M.A. Ghannoum, Clin. Microbiol. Infect. 2019, 25, 792.
• [22] A. León, M. Del-Ángel, J.L. Ávila, G. Delgado, Prog Chem. Org. Nat. Prod. 2017, 104, 127.
• [23] C. Ding, Y. Sheng, Y. Zhang, J. Zhang, G. Du, Planta Med. 2008, 74, 1684.
• [24] R.M. Spréa,; Â. Fernandes,.; T.C. Finimundy,; C. Pereira,; M.J. Alves,; R.C. Calhelha,; C. Canan,; L. Barros, J.S. Amaral, I.C.F.R. Ferreira, Resources 2020, 9, 81.
• [25] A. León, R.A. Toscano, J. Tortoriello, G. Delgado, Nat. Prod. Res. 2011, 25, 1234.
• [26] J.J. Beck, S.-C Chou,. J. Nat. Prod. 2007, 70, 891.
• [27] R.A. Momin, M.G. Nair, J. Agric. Food Chem. 2001, 49, 142.
• [28] J. Pannek, J. Gach, F. Boratyński, T.Olejniczak, Phytother. Res. 2018, 32, 1459.
• [29] L. Fan,; B. Luo,; Z. Luo,; L. Zhang,; J. Fan,; W. Xue,; L.Tang,; Y. Li, Für Nat. B 2019, 74, 811.
• [30] B. Xiao,; J. Yin,; M. Park,; J. Liu,; J.L. Li,; E. Kim,; J. Hong,; H.Y. Chung,; J.H. Jung, Bioorg. Med.Chem. 2012, 20, 4954
• [31] J. Jia, C. Wei, J. Liang, A. Zhou, X. Zuo, H. Song, L. Wu, X. Chen, S. Chen, J. Zhang, i inni Allzheimer’s Dement. 2016, 12, 89.
• [32] X. Wang, L. Wang, X. Sheng, Z. Huang, T. Li, M. Zhang, J. Xu, H. Ji, J. Yin, Y. Zhang, Org. Biomol. Chem. 2014, 12, 5995.
• [33] X. Diao, P. Deng, C. Xie, X. Li, D. Zhong, Y. Zhang, X. Chen, Drug Metab. Dispos. 2013, 41, 430.
• [34] J. Gach, T. Olejniczak, P. Krężel, F. Boratyński, Int. J. Mol. Sci. 2021, 22, 7600.
• [35] X. Chen, S. Deng, Q. Lei, Q. He, Y. Ren,; Y. Zhang, J. Nie,; W. Lu, Front. Cell Dev. Biol. 2020, 8, 598020
• [36] X. Li, X. Wang, L. Miao, Y. Guo, R. Yuan, H. Tian, Biochem. Biophys. Res. Commun. 2021, 556, 99.
• [37] Liu, X.; Liu, R.; Fu, D.; Wu, H.; Zhao, X.; Sun, Y.; Wang, M.; Pu, X. Aging 2021, 13, 3763.
• [38] B. Wang, C. Wu, Z. Chen, P. Zheng, Y. Liu, J. Xiong, J. Xu, P. Li, A.A. Mamun, L. Ye, i inni Acta Pharmacol. Sin. 2021, 42, 347
• [39] Y. Gong, W Liu, X. Huang, L. Hao, Y. Li, S. Sun, Front. Microbiol. 2019, 10, 1461.
• [40] Z. Yan, H. Hua, Y. Xu,; L.P. Samaranayake, Altern. Med. 2012, 12, 1.
• [41] J. Meletiadis, S. Pournaras, E. Roilides, T.J. Walsh, Antimicrob. Agents Chemother. 2010, 54, 602.
• [42] V. Lorian, Antibiotics in Labolatory Medicine, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 200545
• [43] A. Daina, O. Michielin, V. Zoete, SwissADME: Sci. Rep. 2017, 7, 42717.
• [44] D.S. Druzhilovskiy, A.V. Rudik, D.A. Filimonov, T.A. Gloriozova, A.A. Lagunin, A.V. Dmitriev, P.V. Pogodin, V.I. Dubovskaya, S.M. Ivanov, O.A. Tarasova, i inni. Computational platform Way2Drug: Russ. Chem. Bull. 2017, 66, 1832.
• [45] R. Tamaian, A. Moţ, R. Silaghi-Dumitrescu, I. Ionuţ, A. Stana, O. Oniga, C. Nastasă, DBenedec, B. Tiperciuc, Molecules 2015, 20, 22188.
• [46] Lipinski, C.A. Drug Discov. Today Technol 2004, 1, 337.
• [47] T. Chmiel, A. Mieszkowska, D. Kempińska-Kupczyk, A. Kot-Wasik, J. Namieśnik, Z. Mazerska, Microchem. J. 2019, 146, 393.
• [48] G.A. Norman, JACC Basic Transl. Sci. 2020, 5, 387.
• [49] S. Kumar, Expert Opin. Drug Metab. Toxicol. 2010, 6, 11.

Uwagi

PL

Opracowane ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023)